Chinese Pharmacopoeia Microbial Limit Test: Principles, Methods, and Regulatory Requirements

The Chinese Pharmacopoeia (ChP) Microbial Limit Test is a mandatory microbiological quality control procedure that quantifies microbial contamination and detects objectionable organisms in non-sterile pharmaceutical products, raw materials, and excipients. Governed by Chapters 1105, 1106, and 1107 of the ChP 2020 Edition, Volume IV, this test ensures that oral, topical, and other non-sterile preparations meet national safety standards prior to market release. This article provides a comprehensive technical overview of applicable sample types, test items, methodologies, acceptance criteria, and practical applications.

Technical Overview

The Microbial Limit Test (MLT) defined in the Chinese Pharmacopoeia is the official microbiological procedure used to evaluate the bioburden and detect specified objectionable microorganisms in products that are not required to be sterile. The current requirements are established in the ChP 2020 Edition, Volume IV, through three coordinated general chapters:

• Chapter 1105: Microbiological Examination of Non-sterile Products - Microbial Enumeration Tests
• Chapter 1106: Microbiological Examination of Non-sterile Products - Tests for Specified Microorganisms
• Chapter 1107: Acceptance Criteria for Microbiological Quality of Non-sterile Products

These chapters have been substantially harmonized with the corresponding international pharmacopoeial methods, including USP General Chapters <61> and <62>, Ph. Eur. sections 2.6.12 and 2.6.13, and the Japanese Pharmacopoeia. As a result, method design, reference strains, incubation conditions, and acceptance logic are broadly comparable across major pharmacopoeias, which facilitates global regulatory submissions. Testing must be performed under Good Manufacturing Practice (GMP) conditions in qualified microbiology laboratories, and every adopted method must be verified through method suitability testing before routine use.

Testing Samples

The microbial limit test applies to a wide range of non-sterile materials across the pharmaceutical supply chain. Sample handling and preparation are tailored to the physical and chemical nature of each product.

Oral Solid Dosage Forms

Tablets, capsules, granules, and powders are typically ground or suspended to obtain a homogeneous 1:10 dilution in a suitable diluent such as pH 7.0 sterile chloride-peptone buffer or 0.9% sodium chloride solution. Enteric-coated and sustained-release products may require additional dispersion steps.

Oral Liquid Preparations

Syrups, oral solutions, suspensions, emulsions, and tinctures are usually tested directly after dilution. Products containing high sugar concentrations, alcohol, or preservatives demand particular attention during suitability testing because these components can inhibit microbial recovery.

Semi-Solid and Topical Preparations

Creams, ointments, gels, and lotions often require emulsification aids such as polysorbate 80 or isopropyl myristate to ensure adequate dispersion of the sample before dilution and inoculation.

Traditional Chinese Medicine Products

Herbal materials, botanical extracts, and traditional Chinese medicine formulations represent a high-risk category due to their natural origin and potential for inherent antimicrobial activity. These products frequently require membrane filtration with validated neutralization strategies and rigorous method suitability verification.

Raw Materials, Excipients, and Intermediate Products

Active pharmaceutical ingredients, pharmaceutical excipients, and in-process materials are tested against criteria appropriate to their intended use in the final dosage form, as defined in the acceptance criteria tables of Chapter 1107.

Testing Items

The microbial limit test consists of two complementary components: quantitative enumeration of the total bioburden and qualitative detection of specified microorganisms that must be absent for a given route of administration.

Microbial Enumeration Tests

• Total Aerobic Microbial Count (TAMC): performed on tryptic soy (soybean-casein digest) agar, incubated at 30 to 35 degrees Celsius for 3 to 5 days.
• Total Combined Yeasts and Molds Count (TYMC): performed on Sabouraud dextrose agar, incubated at 20 to 25 degrees Celsius for 5 to 7 days.
• Bile-Tolerant Gram-Negative Bacteria (BTGN): enumerated or detected using enterobacteria enrichment broth followed by plating on violet red bile glucose agar.

Tests for Specified Microorganisms

Depending on the product category and route of administration, the following organisms are tested for absence in a defined sample quantity:

• Escherichia coli: required for most oral preparations, reflecting the risk of fecal contamination.
• Salmonella species: required for products of botanical and animal origin with higher contamination risk.
• Staphylococcus aureus: required for topical, nasal, and cutaneous preparations.
• Pseudomonas aeruginosa: required for topical, auricular, and inhaled preparations due to its opportunistic pathogenicity.
• Candida albicans: required for vaginal and certain mucosal preparations.

Acceptance Criteria Overview

Chapter 1107 assigns limits by product category and route of administration. Representative examples include the following:

• Aqueous oral preparations: TAMC not more than 100 CFU per mL and TYMC not more than 10 CFU per mL, with Escherichia coli and bile-tolerant Gram-negative bacteria absent.
• Non-aqueous oral preparations: TAMC not more than 1,000 CFU per gram and TYMC not more than 100 CFU per gram.
• Topical, nasal, and mucosal preparations: absence of Staphylococcus aureus and Pseudomonas aeruginosa, with correspondingly low count limits.

Consistent with international harmonized practice, a stated count limit is interpreted together with a defined maximum acceptable count, typically twice the stated limit, to account for the variability inherent in microbiological measurement.

Testing Methods

Sample Preparation

A representative sample is suspended in a sterile diluent to prepare a 1:10 dilution, followed by serial tenfold dilutions as needed. Where products exhibit antimicrobial activity, validated neutralizing agents such as lecithin, polysorbate 20 or 80, or sodium thiosulfate are incorporated into the diluent.

Plate Count Method

The pour-plate or spread-plate technique is applied using duplicate plates per dilution. After incubation, colonies are counted and results are calculated as colony-forming units per gram or per milliliter, accounting for dilution factors.

Membrane Filtration Method

This is the preferred method for products with intrinsic antimicrobial properties. The sample is passed through a 0.45 micrometer membrane filter, rinsed to remove inhibitory substances, and the membrane is transferred to the appropriate agar medium for incubation.

Most Probable Number Method

The MPN technique, based on triplicate tubes across multiple dilution levels, may be used for products expected to carry very low bioburden, providing a statistical estimate of microbial concentration.

Detection of Specified Microorganisms

Detection follows a three-stage sequence: pre-enrichment in a non-selective or mildly selective broth, subculture onto selective or differential agar media, and confirmation of presumptive colonies using biochemical tests, serological methods, or modern identification tools such as MALDI-TOF mass spectrometry and DNA-based assays.

Method Suitability Testing

Before routine testing, the method must be demonstrated as capable of recovering microorganisms in the presence of the product. This is achieved by inoculating samples with low levels of reference strains obtained from recognized culture collections, including Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Aspergillus niger, and Escherichia coli. The recovery of each strain must fall within the acceptance range specified by the pharmacopoeia; otherwise, the method must be modified with additional neutralization or alternative techniques.

Controls and Incubation

Positive controls using the reference strains and negative controls using the diluent are included in every run to validate media performance and aseptic technique. Incubation conditions follow the harmonized specifications for each medium and target organism, with reading at defined intervals and extension where growth is delayed.

Applications

• Batch release testing of non-sterile finished dosage forms for the domestic Chinese market and NMPA-regulated products.
• Qualification of active pharmaceutical ingredients, excipients, and botanical raw materials prior to use in manufacturing.
• Support of stability programs, where microbial limit data demonstrate that microbiological quality is maintained over the product shelf life.
• Investigation of microbial deviation and out-of-specification results, including source tracing and contamination control assessments.
• Regulatory submissions and export compliance, supported by the strong alignment between ChP methods and USP, Ph. Eur., and JP requirements.
• Evaluation of preservative effectiveness programs for multi-dose non-sterile products in conjunction with antimicrobial efficacy testing.

FAQ

What is the difference between the microbial limit test and the sterility test?

The microbial limit test applies to non-sterile products and permits a defined, limited bioburden while prohibiting specified organisms. The sterility test applies to products labeled as sterile and requires the complete absence of viable microorganisms.

Which chapters of the Chinese Pharmacopoeia govern the microbial limit test?

Chapters 1105, 1106, and 1107 of the ChP 2020 Edition, Volume IV, govern enumeration methods, tests for specified microorganisms, and acceptance criteria, respectively.

When must method suitability testing be performed?

Suitability testing must be completed before first use of a method for a given product, and it must be repeated whenever the product formulation, manufacturing process, or test method changes in a way that could affect microbial recovery.

How does the ChP method compare with USP and Ph. Eur. methods?

The ChP methods are substantially harmonized with USP Chapters <61> and <62> and Ph. Eur. sections 2.6.12 and 2.6.13 in terms of media, reference strains, incubation conditions, and acceptance logic, though procedural details and product-specific criteria should always be verified against the current edition.

How long does a microbial limit test take to complete?

A routine test typically requires 5 to 7 days of incubation for enumeration plus several additional days for the detection and confirmation of specified microorganisms, with the overall timeline depending on the product category and confirmation strategy.

How much sample is required for testing?

Generally, a minimum of 10 grams or 10 milliliters of representative sample is required to prepare the primary 1:10 dilution, with additional quantities needed for parallel enumeration tests and the detection of each specified microorganism.